[{"id":"22513496-b57b-422f-a9cc-b4cffc6c0a59","acronym":"ADCT-601-102","url":"https://clinicaltrials.gov/study/NCT05389462","created_at":"2022-05-25T13:55:41.985Z","updated_at":"2024-07-02T16:35:08.900Z","phase":"Phase 1","brief_title":"A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors","source_id_and_acronym":"NCT05389462 - ADCT-601-102","lead_sponsor":"ADC Therapeutics S.A.","biomarkers":" AXL","pipe":"","alterations":" ","tags":["AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • mipasetamab uzoptirine (ADCT-601)"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 07/13/2022","start_date":" 07/13/2022","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-04-18"},{"id":"101983fb-7628-475a-80b5-d17bf993dca4","acronym":"","url":"https://clinicaltrials.gov/study/NCT02988817","created_at":"2021-12-09T22:53:42.151Z","updated_at":"2024-07-02T16:35:41.314Z","phase":"Phase 1/2","brief_title":"Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors","source_id_and_acronym":"NCT02988817","lead_sponsor":"Genmab","biomarkers":" AXL • MUC16","pipe":" | ","alterations":" AXL expression • AXL positive","tags":["AXL • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AXL expression • AXL positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e enapotamab vedotin (HuMax-AXL-ADC)"],"overall_status":"Completed","enrollment":" Enrollment 306","initiation":"Initiation: 11/23/2016","start_date":" 11/23/2016","primary_txt":" Primary completion: 11/12/2021","primary_completion_date":" 11/12/2021","study_txt":" Completion: 11/12/2021","study_completion_date":" 11/12/2021","last_update_posted":"2023-08-01"}]